Photo taken from google images
Feb 17, 2024, 15:57
Rami Manochakian: The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm NSCLC.
Rami Manochakian, Thoracic Oncologist and Hematology-Oncology Fellowship Director at Mayo Clinic, shared on X/Twitter:
“Hot off the press.
The FDA approves 1st line Osimertinib WITH chemotherapy for advanced EGFRm non-small cell Lung Cancer.
Approval based on FLAURA2 trial which showed PFS compared to Osimertinib alone.
HR: 0.62
mPFS: 25.5 vs 16.7 months.”
View additional information.
Source: Rami Manochakian/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 31, 2025, 20:25
Mar 31, 2025, 20:25
Mar 31, 2025, 20:00
Mar 31, 2025, 19:01
Mar 31, 2025, 18:51
Mar 31, 2025, 18:40
Mar 31, 2025, 18:40